Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP
Hospital das Clínicas da Faculdade de Medicina da São Paulo - USP
Rua Dr. Ovídio Pires de Campos 785 - Estado de São Paulo 05403-000
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Mario Rodrigues Louzã Neto
Dr. T C Barbosa
Josefina Nacarato
Thais Colapietro Barbosa
Paula Martins
Thais Guida Barbosa
Vanderson Rocha
João Victor Bastos Vitagliano
Open studies
Alzheimer disease
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 - DIAN-TU - Avid RadiopharmaceuticalsSee more
Lymphoma
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma - EPCORE FL-1 - AbbVieSee more
Nephropathy
A Study to Evaluate the Efficacy and Safety of RO7434656 in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression - IMAGINATION - Hoffmann-La RocheSee more
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy - ASSIST - Chinook Therapeutics, Inc.See more
Non-Hodgkin Lymphoma
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma - EPCORE FL-1 - AbbVieSee more
A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) - EPCORE DLBCL-2 - AbbVieSee more
Arthritis
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis. - SELECT-sJIA - AbbVieSee more
Extrapyramidal and movement disorders
Effects of rTSMS Associated With Treadmill Training in Patients With Parkinson's Disease - University of Sao Paulo General HospitalSee more
Graft versus Host Disease
A Study to Test an Oral Medicine, Belumosudil, in Combination With Corticosteroids in Participants at Least 12 Years of Age With Newly Diagnosed Chronic Graft Versus Host Disease. - ROCKnrol-1 - SanofiSee more
Hidradenitis suppurativa
A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Step-Up HS - AbbVieSee more
Lupus
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants - POSTERITY - Hoffmann-La RocheSee more
Myasthenia gravis
A Study to Test How Safe Pozelimab and Cemdisiran Combination Therapy and Cemdisiran Alone Are and How Well They Work in Adult Patients With Generalized Myasthenia Gravis - NIMBLE - Regeneron PharmaceuticalsSee more
Obesity
A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight - UNLIMITED - Eurofarma Laboratorios S.A.See more
Rare diseases
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) - MK-1026-003 - Merck Sharp & Dohme Corp.See more
Schizophrenia
Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2) - CONNEX-1 CONNEX-2 CONNEX-3 - Boehringer IngelheimSee more
